Recent advances in the development of acetyl-CoA carboxylase (ACC) inhibitors for the treatment of metabolic disease.

@article{Bourbeau2015RecentAI,
  title={Recent advances in the development of acetyl-CoA carboxylase (ACC) inhibitors for the treatment of metabolic disease.},
  author={Matthew P Bourbeau and Michael D Bartberger},
  journal={Journal of medicinal chemistry},
  year={2015},
  volume={58 2},
  pages={525-36}
}
The development of acetyl-CoA carboxylase (ACC) inhibitors for the treatment of metabolic disease has been pursued by the pharmaceutical industry for some time. A number of recent disclosures describing potent ACC inhibitors have been reported by multiple research groups. Unlike many prior publications in this area, more recent publications contain a significant amount of in vivo efficacy data generated by long-term experiments in rodent models of metabolic disease. Additionally, one compound… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 65 references

Acetyl - CoA Carboxylase Inhibition by ND 646 Reduces Fatty Acid Synthesis and Inhibits Cell Proliferation in Human Non - Small Cell Clung Cancer Cells

R. U. Svensson, G. Harriman, +4 authors R. J. Shaw
Presented at the 105 th Annual Meeting of the American Association for Cancer Research • 2014

Decreases Hepatocellular Carcinoma Development in Cirrhotic Rats. Presented at the 105th Annual Meeting of the American Association for Cancer Research, 2014; Abstract 1427

R. U. Svensson, G. Harriman, +5 authors R. J. Shaw
2014

Liver Selective Acetyl - CoA Carboxylase Inhibition by ND654 Decreases Hepatocellular Carcinoma Development in Cirrhotic Rats

D. K. DePeralta, L. Wei, +7 authors B. C. Fuchs
Presented at the 105 th Annual Meeting of the American Association for Cancer Research • 2014

ACC Inhibitors and Uses Thereof

G. C. Harriman, C. E. Masse, J. Harwood, S. Bhat, J. R. Greenwood
WO Patent Application • 2013

Acetyl - CoA Carboxylase Inhibition by NDI630 Inhibits Fatty Acid Synthesis , Stimulates Fatty Acid Oxidation , Reduces Body Weight , Improves Insulin Sensitivity , and Modulates Dyslipidemia in Rats

G. C. Harriman, J. R. Greenwood, S. Bhat, R. Kapeller, H. J. Harwood
Presented at the 73 rd Annual Scienti fi c Sessions of the American Diabetes Association • 2013

Acetyl-CoA Carboxylase Inhibition by NDI-630 Inhibits Fatty Acid Synthesis, Stimulates Fatty Acid Oxidation, Reduces Body Weight, Improves Insulin Sensitivity, and Modulates Dyslipidemia

G. C. Harriman, J. R. Greenwood, S. Bhat, R. Kapeller, H. J. Harwood
2013

Carboxylase Inhibition

D. P. Canterbury, C.E.N. Scott, +3 authors G. C. Micalizio
Expert Opin. Ther. Targets 2005, • 2013

New Azetidine Derivatives , Pharmaceutical Compositions and Uses Thereof

M. Fleck, B. Nosse, G. J. Roth
WO Patent Application • 2013

New Azetidine Derivatives, Pharmaceutical Compositions and Uses Thereof

M. Fleck, B. Nosse, G. J. Roth
WO Patent Application 2013/098375, • 2013

Similar Papers

Loading similar papers…